Leavell Investment Management Inc. Boosts Holdings in Eli Lilly and Company $LLY

Key Points

• Leavell Investment Management Inc. raised its stake in Eli Lilly and Company by 13.6% during the second quarter, owning a total of 8,576 shares valued at approximately $6.68 million.
• Eli Lilly's CEO, David A. Ricks, purchased 1,632 shares at an average price of $644.77 per share, increasing his ownership to 546,601 shares with a total value of around $352 million.
• The company reported strong earnings with $6.31 EPS for the quarter, exceeding estimates, and expects fiscal year 2025 guidance to reach 21.750–23.000 EPS.

Leavell Investment Management Inc. increased its stake in shares of Eli Lilly and Company (NYSE:LLY - Free Report) by 13.6% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 8,576 shares of the company's stock after purchasing an additional 1,029 shares during the quarter. Leavell Investment Management Inc.'s holdings in Eli Lilly and Company were worth $6,685,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the business. WestEnd Advisors LLC lifted its holdings in Eli Lilly and Company by 210.0% in the 1st quarter. WestEnd Advisors LLC now owns 31 shares of the company's stock worth $26,000 after buying an additional 21 shares in the last quarter. Wealth Preservation Advisors LLC acquired a new stake in shares of Eli Lilly and Company during the 1st quarter valued at approximately $27,000. Blume Capital Management Inc. increased its position in Eli Lilly and Company by 46.7% in the second quarter. Blume Capital Management Inc. now owns 44 shares of the company's stock worth $34,000 after buying an additional 14 shares during the period. Citizens National Bank Trust Department increased its position in Eli Lilly and Company by 180.0% in the first quarter. Citizens National Bank Trust Department now owns 42 shares of the company's stock worth $35,000 after buying an additional 27 shares during the period. Finally, IMG Wealth Management Inc. acquired a new stake in Eli Lilly and Company in the second quarter worth $35,000. Hedge funds and other institutional investors own 82.53% of the company's stock.

Insider Activity

In related news, CEO David A. Ricks purchased 1,632 shares of Eli Lilly and Company stock in a transaction that occurred on Tuesday, August 12th. The shares were acquired at an average price of $644.77 per share, with a total value of $1,052,264.64. Following the completion of the transaction, the chief executive officer directly owned 546,601 shares of the company's stock, valued at $352,431,926.77. This represents a 0.30% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Daniel Skovronsky acquired 1,000 shares of the business's stock in a transaction that occurred on Tuesday, August 12th. The shares were purchased at an average cost of $634.40 per share, for a total transaction of $634,400.00. Following the acquisition, the executive vice president owned 137,660 shares in the company, valued at $87,331,504. This represents a 0.73% increase in their ownership of the stock. The disclosure for this purchase can be found here. In the last ninety days, insiders acquired 4,514 shares of company stock valued at $2,894,841. Corporate insiders own 0.13% of the company's stock.

Eli Lilly and Company Stock Performance

LLY traded up $4.82 during midday trading on Friday, reaching $825.86. The company's stock had a trading volume of 2,207,377 shares, compared to its average volume of 3,510,202. Eli Lilly and Company has a twelve month low of $623.78 and a twelve month high of $935.63. The stock has a market cap of $781.65 billion, a P/E ratio of 53.98, a PEG ratio of 1.18 and a beta of 0.47. The company has a fifty day simple moving average of $768.01 and a 200 day simple moving average of $768.14. The company has a current ratio of 1.28, a quick ratio of 1.00 and a debt-to-equity ratio of 1.86.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last announced its quarterly earnings results on Thursday, August 7th. The company reported $6.31 EPS for the quarter, beating the consensus estimate of $5.59 by $0.72. The business had revenue of $15.56 billion for the quarter, compared to analyst estimates of $14.40 billion. Eli Lilly and Company had a return on equity of 92.72% and a net margin of 25.91%.Eli Lilly and Company's quarterly revenue was up 37.6% on a year-over-year basis. During the same quarter in the previous year, the firm earned $3.92 EPS. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. Research analysts expect that Eli Lilly and Company will post 23.48 earnings per share for the current year.

Analysts Set New Price Targets

Several equities research analysts have weighed in on LLY shares. Hsbc Global Res raised Eli Lilly and Company from a "moderate sell" rating to a "hold" rating in a research report on Wednesday, August 27th. Leerink Partnrs lowered Eli Lilly and Company from a "strong-buy" rating to a "hold" rating in a research report on Thursday, August 7th. Weiss Ratings reissued a "hold (c+)" rating on shares of Eli Lilly and Company in a report on Friday. Deutsche Bank Aktiengesellschaft lowered their price target on Eli Lilly and Company from $1,010.00 to $900.00 and set a "buy" rating on the stock in a report on Monday, August 11th. Finally, Berenberg Bank reissued a "hold" rating and set a $830.00 price target (down from $970.00) on shares of Eli Lilly and Company in a report on Wednesday, September 17th. One investment analyst has rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and nine have issued a Hold rating to the stock. According to MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $938.61.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.